Clinical trials: Recurrent Non-Small Cell Lung Carcinoma
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054392
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 57 sites in United States
- Sponsor
- Fox Chase Cancer Center
Lung Cancer - Non Small Cell Squamous
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
- Trial name
- NCT01285609
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 290 sites in United States, Argentina and 34 more
- Volunteers
- 1,289 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Small Cell Lung Carcinoma
ZD6474 Phase IIa Dose Finding Multicentre Study
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
- Trial name
- NCT00252746
- Testing
- ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg
- Where
- 7 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Genzyme, a Sanofi Company
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of the experimental drug, entinostat, in women with breast cancer and men and women with non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
- Trial name
- ENCORE110 (NCT01594398)
- Testing
- entinostat, Erlotinib, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Syndax Pharmaceuticals
Non Small Cell Lung Cancer
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
Lung cancer is one of the diseases with the highest global incidence and mortality. Studies have confirmed that liquid biopsy markers such as minimal residual disease (MRD) detection in solid tumors, circulating tumor DNA…
- Trial name
- NCT07057102
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer (Non-Small Cell), Lung Metastases From Any Primary
Evaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing Function
This clinical study is evaluating different treatment options for patients with malignant lung tumors, including both primary lung cancer and tumors that have spread to the lungs from other parts of the body.
- Trial name
- NCT07272356
- Testing
- Surgery, Ablation, SBRT
- Where
- Lithuania
- Volunteers
- 68 people
- Sponsor
- Aurimas Macionis
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects of soy isoflavones when given together with radiation therapy and chemotherapy in treating patients with stage IIIA-IIIB non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT01958372
- Testing
- soy isoflavones, cisplatin, etoposide
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00017407
- Testing
- ISIS 3521, carboplatin, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer
The purposes of this study are to test whether the addition of cisplatin to single agent chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with non squamous non small cell lung cancer (NSCLC)…
- Trial name
- MILES-4 (NCT01656551)
- Testing
- Gemcitabine, Pemetrexed, Cisplatin
- Where
- 48 sites in Italy
- Volunteers
- 232 people
- Sponsor
- National Cancer Institute, Naples
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva and that of standard of care chemotherapy in patients with advanced, recurrent, or metastatic NSCLC experiencing disease progression after…
- Trial name
- NCT00556322
- Testing
- Alimta or Taxotere, erlotinib [Tarceva]
- Where
- 123 sites in Australia, Austria and 25 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a…
- Trial name
- NCT05633602
- Testing
- Chemotherapy, Pembrolizumab, Ramucirumab
- Where
- 566 sites in United States
- Volunteers
- 838 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00104767
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.
- Trial name
- LUCAS (NCT05786430)
- Testing
- Lazertinib/Pemetrexed/Carboplatin
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Yonsei University
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04092283
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 830 sites in United States, Guam
- Volunteers
- 660 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
- Trial name
- NCT05669846
- Testing
- Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Diwakar Davar